Form 4: Zimmer Biomet Director Kolli Sreelakshmi Reports Acquisition of Phantom Stock Units

Director Kolli Sreelakshmi reports acquiring phantom stock units in Zimmer Biomet Holdings, Inc. through a deferred compensation plan.

Summary

• On March 31, 2024, Kolli Sreelakshmi, a director of Zimmer Biomet Holdings, Inc., acquired 117.702 phantom stock units at a price of $0.
• These units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
• The units will be settled in shares of company common stock within sixty days after Kolli Sreelakshmi ceases to be a director.
• Following the reported transaction, Kolli Sreelakshmi beneficially owns 3,006.067 phantom stock units.
• This amount includes 5.258 phantom stock units accrued on January 31, 2024, under the dividend reinvestment provision of the same deferred compensation plan.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a routine transaction related to director compensation, which is a normal part of corporate governance. The acquisition of phantom stock units suggests confidence in the company's future performance.

Positives

• The acquisition of phantom stock units aligns the director's interests with the long-term performance of the company.
• The deferred compensation plan encourages directors to remain invested in the company's success.

Future Outlook

The phantom stock units will be settled in shares of Zimmer Biomet common stock within sixty days after Kolli Sreelakshmi ceases to be a director.

Industry Context

This filing is a routine disclosure related to director compensation and is typical for publicly traded companies like Zimmer Biomet. It reflects standard practices for incentivizing board members.

Comparison to Industry Standards

• Deferred compensation plans, including phantom stock units, are a common method of compensating directors in publicly traded companies, particularly in the healthcare and medical device industries.
• Companies like Medtronic and Stryker also utilize similar compensation strategies to align director interests with shareholder value.
• The specific number of units and terms of the plan are company-specific and depend on factors such as company size, performance, and compensation philosophy.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders.
• It reinforces the alignment of director interests with shareholder value through equity-based compensation.

Key Dates